Agios Pharm (AGIO)

Celgene buying out Agios would make sense but either way the company's work on cellular metabolism and gene deleting is interesting the bulls the most. Agios stock is a good buy on its own merits.

7 ‘Strong Buy’ Stocks With 100% Wall Street Support

By Harriet Lefton, Writer, TipRanks Nov 17, 2017

These seven rare stocks have received only "buy" ratings from Wall Street's best analysts, with more upside predicted to come.

Liberty Sirius XM Group (LSXMK) Lead 12 Activist Investor Reports

By Fintel Apr 25, 2017

Recent 13-D and 13-G filings are windows into activist investors activity. We look at Liberty Sirius XM Group and 11 others

40 Biotechnology Stocks to Sell Now

By Portfolio Grader Dec 12, 2016

This week, the overall grades of 40 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

40 Biotechnology Stocks to Sell Now

By Portfolio Grader Dec 5, 2016

The overall ratings of 40 Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

Why Agios Pharmaceuticals Inc (AGIO), LPL Financial Holdings Inc (LPLA) and Humana Inc (HUM) Are 3 of Today’s Worst Stocks

By James Brumley, InvestorPlace Feature Writer Dec 5, 2016

Agios (AGIO), LPL Financial (LPLA) and Humana (HUM) were wishing the weekend could have lasted one more day on Monday.

Agios Pharm (AGIO)

AGIO Stock Earnings: Agios Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024

The 3 Best Biotech Stocks to Buy Now: Q2 Edition

7 Biotech Stocks Fighting America’s Deadliest Diseases

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

Agios Pharm (AGIO)

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

AGIO Stock Predictions, Articles, and Agios Pharm News

Subscriber Sign in